基层医学论坛
基層醫學論罈
기층의학론단
PUBLIC MEDICAL FORUM MAGAZINE
2014年
1期
12-13,14
,共3页
呼吸机相关性肺炎%耐甲氧西林金黄色葡萄球菌%利奈唑胺%万古霉素
呼吸機相關性肺炎%耐甲氧西林金黃色葡萄毬菌%利奈唑胺%萬古黴素
호흡궤상관성폐염%내갑양서림금황색포도구균%리내서알%만고매소
Ventilator-associated pneumonia%Meticillin-resistant staphylococcus aureus%Linezolid%Vancomycin
目的：观察比较利奈唑胺和万古霉素治疗耐甲氧西林金黄色葡萄球菌（MRSA）呼吸机相关性肺炎（VAP）的临床效果和不良反应。方法将88例MRSA所致VAP患者随机分为2组，治疗组和对照组各44例。治疗组采用利奈唑胺治疗，对照组采用万古霉素治疗。2组疗程均为14 d，观察2组的临床疗效和不良反应。结果MRSA清除率治疗组为79.55%，对照组为56.82%；治疗组总有效率为74.00%，对照组为52.00%，2组比较，治疗组清除率、总有效率均优于对照组（P<0.05）。不良反应发生率治疗组为11.36%，对照组为13.64%，2组比较差异无统计学意义（P>0.05）。结论利奈唑胺对MRSA所致VAP有较好的临床疗效，毒副作用与万古霉素相当。
目的：觀察比較利奈唑胺和萬古黴素治療耐甲氧西林金黃色葡萄毬菌（MRSA）呼吸機相關性肺炎（VAP）的臨床效果和不良反應。方法將88例MRSA所緻VAP患者隨機分為2組，治療組和對照組各44例。治療組採用利奈唑胺治療，對照組採用萬古黴素治療。2組療程均為14 d，觀察2組的臨床療效和不良反應。結果MRSA清除率治療組為79.55%，對照組為56.82%；治療組總有效率為74.00%，對照組為52.00%，2組比較，治療組清除率、總有效率均優于對照組（P<0.05）。不良反應髮生率治療組為11.36%，對照組為13.64%，2組比較差異無統計學意義（P>0.05）。結論利奈唑胺對MRSA所緻VAP有較好的臨床療效，毒副作用與萬古黴素相噹。
목적：관찰비교리내서알화만고매소치료내갑양서림금황색포도구균（MRSA）호흡궤상관성폐염（VAP）적림상효과화불량반응。방법장88례MRSA소치VAP환자수궤분위2조，치료조화대조조각44례。치료조채용리내서알치료，대조조채용만고매소치료。2조료정균위14 d，관찰2조적림상료효화불량반응。결과MRSA청제솔치료조위79.55%，대조조위56.82%；치료조총유효솔위74.00%，대조조위52.00%，2조비교，치료조청제솔、총유효솔균우우대조조（P<0.05）。불량반응발생솔치료조위11.36%，대조조위13.64%，2조비교차이무통계학의의（P>0.05）。결론리내서알대MRSA소치VAP유교호적림상료효，독부작용여만고매소상당。
Objective To explore the efficacy and safety of linezolid and vancomycin in the treatment of ventilator-associated pneumonia (VAP)caused by meticillin-resistant Staphylococcus aureus (MRSA)so as to guide the clinical diagnosis and treatment. Methods A total of 68cases of patients with VAP caused by MRSA were randomly divided into the linezolid group (n=34)and the vancomycin group (n=34).All the treatment courses were 7-14days.The clinical effect,bacterial clearance rate,inflammatory reaction and side effect were observed and compared. Results The bacterial clearance rate and the total effective rate of the linezolid group were respectively 79.55%and 64.7%,significantly higher than74.00%and 52.00%of the vancomycin group ,the difference was statistically significant(P<0.05).The levels of white blood cell,C-reactive protein and procalcitonin in both groups were significantly decreased compared with those before the treatment (P<0.05),while those indicators were decreased more remarkably in the linezolid group than in the vancomycin group,the difference was statistically significant (P<0.05).The incidence rate of the adverse reaction was 11.36% in the linezolid group and13.64%in the vancomycin group ,the difference was not statistically significant. Conclusion Linezolid is more effective than vancomycin in the treatment of VAP caused by MRSA ,it can remarkably raise the bacterial clearance rate and reduce the pulmonary inflammatory reactions ,with less adverse reactions caused.
